LT4419526T - Heterocikliniai junginiai, skirti vėžiui gydyti - Google Patents

Heterocikliniai junginiai, skirti vėžiui gydyti

Info

Publication number
LT4419526T
LT4419526T LTEPPCT/GB2022/052690T LTGB2022052690T LT4419526T LT 4419526 T LT4419526 T LT 4419526T LT GB2022052690 T LTGB2022052690 T LT GB2022052690T LT 4419526 T LT4419526 T LT 4419526T
Authority
LT
Lithuania
Prior art keywords
cancer
treatment
heterocyclic compounds
heterocyclic
compounds
Prior art date
Application number
LTEPPCT/GB2022/052690T
Other languages
English (en)
Lithuanian (lt)
Inventor
Owen Davis
Robert Heald
Martin Stockley
Harry Finch
Sam MANN
Original Assignee
Artios Pharma Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artios Pharma Limited filed Critical Artios Pharma Limited
Publication of LT4419526T publication Critical patent/LT4419526T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LTEPPCT/GB2022/052690T 2021-10-21 2022-10-21 Heterocikliniai junginiai, skirti vėžiui gydyti LT4419526T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2115156.8A GB202115156D0 (en) 2021-10-21 2021-10-21 Novel compounds
PCT/GB2022/052690 WO2023067356A1 (en) 2021-10-21 2022-10-21 Heterocyclic compounds for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
LT4419526T true LT4419526T (lt) 2025-03-25

Family

ID=78805918

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/GB2022/052690T LT4419526T (lt) 2021-10-21 2022-10-21 Heterocikliniai junginiai, skirti vėžiui gydyti

Country Status (24)

Country Link
US (1) US20240425511A1 (https=)
EP (2) EP4419526B1 (https=)
JP (2) JP2024539132A (https=)
KR (1) KR20240099274A (https=)
CN (2) CN119053600A (https=)
AR (1) AR127431A1 (https=)
AU (1) AU2022374050A1 (https=)
CA (1) CA3233255A1 (https=)
DK (1) DK4419526T3 (https=)
ES (1) ES3008687T3 (https=)
FI (1) FI4419526T3 (https=)
GB (1) GB202115156D0 (https=)
HR (1) HRP20250334T1 (https=)
HU (1) HUE070568T2 (https=)
IL (1) IL311922A (https=)
LT (1) LT4419526T (https=)
MX (1) MX2024004874A (https=)
PL (1) PL4419526T3 (https=)
PT (1) PT4419526T (https=)
RS (1) RS66620B1 (https=)
SI (1) SI4419526T1 (https=)
SM (1) SMT202500123T1 (https=)
TW (1) TW202334150A (https=)
WO (2) WO2023067355A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025077896A1 (zh) * 2023-10-12 2025-04-17 上海湃隆生物科技有限公司 一种DNA聚合酶theta抑制剂及其应用
CN118084767B (zh) * 2024-04-02 2025-06-17 康龙化成手性医药技术(宁波)有限公司 一种外型-6-氟甲基-3-氮杂双环[3,1,0]己烷盐酸盐及其衍生物的合成方法
WO2025214463A1 (zh) * 2024-04-13 2025-10-16 正大天晴药业集团股份有限公司 含有三并环结构的化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017062754A1 (en) 2015-10-07 2017-04-13 New York University Compositions and methods for enhancing crispr activity by polq inhibition
US12358886B2 (en) * 2019-08-09 2025-07-15 Artios Pharma Limited Heterocyclic compounds for use in the treatment of cancer

Also Published As

Publication number Publication date
PL4419526T3 (pl) 2025-04-22
SMT202500123T1 (it) 2025-05-12
EP4419527A1 (en) 2024-08-28
HRP20250334T1 (hr) 2025-06-06
US20240425511A1 (en) 2024-12-26
JP2024542949A (ja) 2024-11-19
DK4419526T3 (da) 2025-02-17
EP4419526A1 (en) 2024-08-28
ES3008687T3 (en) 2025-03-24
FI4419526T3 (fi) 2025-02-13
CA3233255A1 (en) 2023-04-27
PT4419526T (pt) 2025-02-03
RS66620B1 (sr) 2025-04-30
WO2023067355A1 (en) 2023-04-27
EP4419526B1 (en) 2024-12-25
CN119053600A (zh) 2024-11-29
IL311922A (en) 2024-06-01
JP2024539132A (ja) 2024-10-28
CN118234728A (zh) 2024-06-21
KR20240099274A (ko) 2024-06-28
GB202115156D0 (en) 2021-12-08
WO2023067356A1 (en) 2023-04-27
SI4419526T1 (sl) 2025-05-30
AU2022374050A1 (en) 2024-05-02
AR127431A1 (es) 2024-01-24
HUE070568T2 (hu) 2025-06-28
TW202334150A (zh) 2023-09-01
MX2024004874A (es) 2024-05-06

Similar Documents

Publication Publication Date Title
LT3986897T (lt) Egfr inhibitorius, skirtas vėžiui gydyti
CY1125245T1 (el) Ετεροκυκλικες ενωσεις ως αναστολεις ρι3κ-γαμμα
CY1126855T1 (el) Ενωσεις κυκλικων δινουκλεοτιδιων για τη θεραπευτικη αγωγη καρκινου
CY1124046T1 (el) Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
CY1125145T1 (el) Αναστολεις cd73
HUE050155T2 (hu) 1-tetrahidropiranilkarbonil-2,3-dihidro-1H-indol vegyületek rák kezelésére
LT3755703T (lt) N-(fenil)-2-(fenil)pirimidin-4-karboksamido dariniai ir susiję junginiai, kaip hpk1 inhibitoriai, skirti vėžio gydymui
IL281427A (en) Compounds for treating certain leukemias
HUE060711T2 (hu) Makrociklusos vegyületek betegségek kezelésére
HUE053191T2 (hu) 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
JOP20190254A1 (ar) مركبات مضادة للأورام
IL290363A (en) Ripretinib for treating gastrointestinal stromal tumors
LT4419526T (lt) Heterocikliniai junginiai, skirti vėžiui gydyti
EA201591509A1 (ru) Ингибиторы cdc7
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201890594A1 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
PT4013412T (pt) Ripretinib para o tratamento de tumores estromais gastrointestinais
LT3416957T (lt) 6-heterociklil-4-morfolin-4-ilpiridin-2-ono junginiai, tinkami vėžio ir diabeto gydymui
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
EA201792287A1 (ru) Способы лечения рака
IL281845A (en) Combination therapy for the treatment of cancer
IL282700A (en) Heterocyclic compounds for the treatment of epilepsy
IL289201A (en) Compounds for the treatment of cancer
EP4025203A4 (en) CANCER TREATMENT